Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Pulmonary sarcomatoid carcinoma (PSC) is a poorly differentiated non-small cell lung cancer (NSCLC) that contains components of spindle or giant cells. Owing to its low prevalence, there are insufficient data regarding its clinical features, therapeutic strategies and prognosis. Methods: The medical records of 26 patients diagnosed with PSC from January 2009 to June 2015 were reviewed and analyzed for clinicopathological characteristics, treatment modality, and outcomes. Results: The median age was 69.5 years. Twenty-three patients (88%) were male. Twenty-four patients (92%) were smokers. The median time from symptom onset to diagnosis was one month. Eighteen patients (69%) were diagnosed at an advanced stage. Pleomorphic carcinoma was the most common subtype, and epidermal growth factor receptor (EGFR) mutation was positive in two of 11 patients. Among 13 patients tested for programmed death ligand 1 (PD-L1) immunohistochemistry assay, eight showed high expression of PD-L1. The median overall survival (OS) of all patients was 9.5 months. In total, 12 patients were treated with chemotherapy: nine with platinum-based doublet therapy, two with tyrosine kinase inhibitor, and one with docetaxel. Seven patients showed partial response or stable disease. The median OS and progression-free survival of patients who received chemotherapy were 8.7 and 2.8 months, respectively. Conclusions: PSC was more common in males, smokers, and the elderly, with worse prognosis than ordinary NSCLC; chemotherapy response was favorable, and EGFR mutation status and PD-L1 expression may offer more therapeutic options.
Abstract
Background/Aims: Pulmonary sarcomatoid carcinoma (PSC) is a poorly differentiated non-small cell lung cancer (NSCLC) that contains components of spindle or giant cells. Owing to its low prevalence, there are insufficient data regarding its clinical features, therapeutic strategies and prognosis. Methods: The medical records of 26 patients diagnosed with PSC from January 2009 to June 2015 were reviewed and analyzed for clinicopathological characteristics, treatment modality, and outcomes. Results: The median age was 69.5 years. Twenty-three patients (88%) were male. Twenty-four patients (92%) were smokers. The median time from symptom onset to diagnosis was one month. Eighteen patients (69%) were diagnosed at an advanced stage. Pleomorphic carcinoma was the most common subtype, and epidermal growth factor receptor (EGFR) mutation was positive in two of 11 patients. Among 13 patients tested for programmed death ligand 1 (PD-L1) immunohistochemistry assay, eight showed high expression of PD-L1. The median overall survival (OS) of all patients was 9.5 months. In total, 12 patients were treated with chemotherapy: nine with platinum-based doublet therapy, two with tyrosine kinase inhibitor, and one with docetaxel. Seven patients showed partial response or stable disease. The median OS and progression-free survival of patients who received chemotherapy were 8.7 and 2.8 months, respectively. Conclusions: PSC was more common in males, smokers, and the elderly, with worse prognosis than ordinary NSCLC; chemotherapy response was favorable, and EGFR mutation status and PD-L1 expression may offer more therapeutic options.
참고문헌 (26)
- Travis WD, "The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification", J Thorac Oncol, 10, pp.1243~1260 (2015)[DOI]
- Yendamuri S, "Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis", Surgery, 152, pp.397~402 (2012)[DOI]
- Park JS, "Clinicopathologic outcomes of curative resection for sarcomatoid carcinoma of the lung", Oncology, 81, pp.206~213 (2011)[DOI]
- Vieira T, "Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma", J Thorac Oncol, 8, pp.1574~1577 (2013)[DOI]
- Pelosi G, "Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases", Am J Surg Pathol, 27, pp.1203~1215 (2003)[DOI]
- Nakajima M, "Sarcomatoid carcinoma of the lung: a clinicopathologic study of 37 cases", Cancer, 86, pp.608~616 (1999)[DOI]
- Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)[DOI]
- Brooks DR, "Influence of type of cigarette on peripheral versus central lung cancer", Cancer Epidemiol Biomarkers Prev, 14, pp.576~581 (2005)[DOI]
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)[DOI]
- Roach C, "Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-smallcell lung cancer", Appl Immunohistochem Mol Morphol, 24, pp.392~397 (2016)[DOI]
- Pelosi G, "Review article: pulmonary sarcomatoid carcinomas: a practical overview", Int J Surg Pathol, 18, pp.103~120 (2010)[DOI]
- Rossi G, "Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases", Am J Surg Pathol, 27, pp.311~324 (2003)[DOI]
- Fishback NF, "Pleomorphic (spindle", giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases, 1994, pp.73, 2936~2945
- Koss MN, "Carcinosarcomas of the lung: a clinicopathologic study of 66 patients", Am J Surg Pathol, 23, pp.1514~1526 (1999)[DOI]
- Martin LW, "Sarcomatoid carcinoma of the lung: a predictor of poor prognosis", Ann Thorac Surg, 84, pp.973~980 (2007)[DOI]
- Bae HM, "Palliative chemotherapy for pulmonary pleomorphic carcinoma", Lung Cancer, 58, pp.112~115 (2007)[DOI]
- Soo RA, "Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials", J Thorac Oncol, 6, pp.1030~1038 (2011)[DOI]
- Chang YL, "EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy", Ann Surg Oncol, 18, pp.2952~2960 (2011)[DOI]
- Tamura Y, "Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma", BMC Res Notes, 8, pp.800~ (2015)[DOI]
- Zou F, "Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: a case report", Oncol Lett, 9, pp.2239~2243 (2015)[DOI]
- Velcheti V, "Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)", J Thorac Oncol, 8, pp.803~805 (2013)[DOI]
- Vieira T, "Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages", Lung Cancer, 98, pp.51~58 (2016)[DOI]
- Kim S, "Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas", Eur J Cancer, 51, pp.2698~2707 (2015)[DOI]
- Shimoji M, "Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)", Lung Cancer, 98, pp.69~75 (2016)[DOI]
- Garon EB, "Pembrolizumab for the treatment of non-small-cell lung cancer", N Engl J Med, 372, pp.2018~2028 (2015)[DOI]
- Dix Junqueira Pinto G, "Evaluation of PD-L1 expression in tumor tissue of patients with lung carcinoma and correlation with clinical and demographic data", J Immunol Res, 2016, pp.9839685~ (2016)